Skip to main content
Top
Published in: Journal of Inherited Metabolic Disease 3/2009

01-06-2009 | SYMPOSIUM ON NEUROTRANSMITTER DISORDERS

Increasing physical function through physiatric intervention for children with paediatric neurotransmitter disorders

Authors: S. Evans, K. Forester, J. M. Pettiford, O. Morozova

Published in: Journal of Inherited Metabolic Disease | Issue 3/2009

Login to get access

Summary

Most children with paediatric neurotransmitter diseases have global functional deficits secondary to central nervous system damage. Paediatric physiatrists, working in conjunction with a multi-disciplinary team, help to improve physical function by normalizing muscle tone and improving body position. Components of spasticity, rigidity, and dystonia may all need to be considered in a comprehensive treatment programme. Complications of disordered tone include skin breakdown, pain, sleep disturbance, and dysphagia. With an integrated approach to use of medications and equipment as well as implementation of therapy and therapeutic exercise, physiatrists can help maximize functional independence for children with this group of disorders. Pharmacological treatment includes GABA-agonists including baclofen and benzodiazepines, alpha-2 adrenergic agonists, l-dopa and dopaminergic agents, and dantrolene. Intrathecal baclofen may be used in patients refractory to these medications. In addition, physicians may utilize botulinum toxin, phenol, or surgical interventions such as selective dorsal rhizotomy or tendon lengthening. Pharmacological treatment must be used in conjunction with appropriate adaptive equipment in order to maximize therapeutic benefit. Focus on function in an attempt to increase independence is targeted to improve the child′s quality of life. We present a framework and rationale to the management of the functional consequences of the paediatric neurotransmitter diseases.
Literature
go back to reference Delisa JA (2008) Aspects of training important to future physical and rehabilitation medicine physicians and our specialty training. J Rehabil Med 40: 785-786PubMed Delisa JA (2008) Aspects of training important to future physical and rehabilitation medicine physicians and our specialty training. J Rehabil Med 40: 785-786PubMed
go back to reference Kolaski K, Ajizian SJ, Passmore L, Pasutharnchat N, et al (2008) Safety profile of multilevel chemical denervation procedures using phenol or botulinum toxin or both in a pediatric population. Am J Phys Med Rehabil 87:556-566PubMedCrossRef Kolaski K, Ajizian SJ, Passmore L, Pasutharnchat N, et al (2008) Safety profile of multilevel chemical denervation procedures using phenol or botulinum toxin or both in a pediatric population. Am J Phys Med Rehabil 87:556-566PubMedCrossRef
go back to reference Koman LA, Mooney JF 3rd, Smith BP, Walker F, Leon JM (2000) Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. BOTOX Study Group. J Pediatr Orthop 20(1): 108-115. doi:10.1097/00004694-200001000-00022 PubMedCrossRef Koman LA, Mooney JF 3rd, Smith BP, Walker F, Leon JM (2000) Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. BOTOX Study Group. J Pediatr Orthop 20(1): 108-115. doi:10.​1097/​00004694-200001000-00022 PubMedCrossRef
go back to reference Koman LA, Smith BP, Balkrishnan R (2003) Spasticity associated with cerebral palsy in children. Guidelines for use of botulinum A toxin. Pediatr Drugs 5: 11-23 Koman LA, Smith BP, Balkrishnan R (2003) Spasticity associated with cerebral palsy in children. Guidelines for use of botulinum A toxin. Pediatr Drugs 5: 11-23
go back to reference Lance JW (1981) Disordered muscle tone and movement. Clin Exp Neurol 18: 27-35PubMed Lance JW (1981) Disordered muscle tone and movement. Clin Exp Neurol 18: 27-35PubMed
go back to reference McLaughlin JF, Bjornson KF, Astley SJ, Graubert C, et al (1998) Selective dorsal rhizotomy: efficacy and safety in an investigator-masked randomized clinical trial. Dev Med Child Neurol 40:220-232PubMedCrossRef McLaughlin JF, Bjornson KF, Astley SJ, Graubert C, et al (1998) Selective dorsal rhizotomy: efficacy and safety in an investigator-masked randomized clinical trial. Dev Med Child Neurol 40:220-232PubMedCrossRef
Metadata
Title
Increasing physical function through physiatric intervention for children with paediatric neurotransmitter disorders
Authors
S. Evans
K. Forester
J. M. Pettiford
O. Morozova
Publication date
01-06-2009
Publisher
Springer Netherlands
Published in
Journal of Inherited Metabolic Disease / Issue 3/2009
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-009-1190-0

Other articles of this Issue 3/2009

Journal of Inherited Metabolic Disease 3/2009 Go to the issue

Symposium on Neurotransmitter Disorders

Disorders of biopterin metabolism

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.